The GLP-1 Maintenance Phase

For the first year on a GLP-1, the story is about loss. The scale moves, clothes fit differently, labs improve. Then somewhere around month 12 to 15, the curve flattens. That's not failure. That's the maintenance phase — the point where the medication's job shifts from "produce loss" to "hold the new set point."

Most people are not prepared for this transition because most marketing focuses on the loss numbers. The reality is that maintenance is where the clinical work of GLP-1 treatment lives long-term. It is also where the chronic-disease framing of obesity becomes most visible.

This guide walks through what defines the maintenance phase, what the trial data shows about long-term continuation, and what changes day-to-day when active loss is no longer the goal.

What the research shows

In the STEP 1 trial of semaglutide 2.4 mg, mean weight loss was approximately 14.9% at week 68 — the primary endpoint that has become the headline number for semaglutide. By that point the loss curve had nearly flattened; the difference between week 60 and week 68 was small. STEP 5, the two-year extension, showed that users who continued on semaglutide held that loss out to week 104 with only marginal additional change. The big loss happened in year one; year two was maintenance.

Tirzepatide follows a similar pattern at a higher overall magnitude. The SURMOUNT-1 program showed mean losses of roughly 20% at week 72 on the 15 mg dose, with a clear flattening as the trial progressed. SURMOUNT-4 then specifically tested maintenance: patients who continued tirzepatide held their loss, while those switched to placebo regained roughly half within a year. The conclusion across both molecules is the same — continued GLP-1 signaling is what sustains the new weight, not residual effects from the loss phase.

The biological reason matters here. GLP-1 medications work in part by lowering the body's defended weight set point through appetite regulation, slower gastric emptying, and changes in reward circuitry around food. When the drug is in your system, the defended weight stays lower. When it is not, the body tends to push back toward its pre-treatment set point. Maintenance dosing keeps that pushback suppressed.

What this looks like day-to-day

In the maintenance phase, the medication mostly fades into the background. Injections become a Sunday-morning routine. Side effects, if they exist at all, are mild and predictable. The scale moves in a narrow band rather than trending down. Many users describe this period as the easiest part of the journey — the hard work of titration, adjustment, and loss is behind them, and the medication is doing maintenance work in the background.

The conversations with your prescriber change too. The annual review focuses on labs, body composition trends, and whether the current dose is still appropriate. Some users stay at their maximum dose. Others step down to a lower maintenance dose for cost, side effects, or because the lower dose holds the loss adequately. There is no single right answer; this is an individual conversation.

The psychological shift is the bigger story for many people. After a year of measuring progress in pounds lost, you have to find new metrics — strength, fitness, energy, lab values, how clothes fit, how food relationships feel. The scale alone is no longer the story. For users who built their identity around active loss, the transition into maintenance can feel anticlimactic until the new frame settles in.

Common questions

Keep exploring

Browse all GLP-1 guides.